Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsVIALStandard

RETAVASE

RETEPLASE

Standard Dose
18.8MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Prescription
Summary

Approval overview RETAVASE is listed in Drugs@FDA under application 103786 (BLA).

Review priority: UNKNOWN Marketing status: Prescription Active ingredient RETEPLASE Form and strength VIAL - 18.8MG/VIAL Sponsor EKR THERAP Submission history Latest submission status date: 1998-05-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview RETAVASE is listed in Drugs@FDA under application 103786 (BLA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient RETEPLASE Form and strength VIAL - 18.8MG/VIAL Sponsor EKR THERAP Submission history Latest submission status date: 1998-05-06 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: UNKNOWN

Interaction Notes

  • No interaction notes stored yet.